Legal Counsel Jarosław Rudy advised the fund operated by Kvarko ASI sp. z o.o. on investments in Auxilius Pharma Oncology sp. z o.o.
Jarosław Rudy, Legal Counsel and Managing Partner of the Żyglicka and Wspólnicy Law Firm, advised Kvarko ASI sp. z o.o. on the investment in Auxilius Pharma Oncology sp. z o.o., which carries out a R&D project.
This is already the 20th joint investment.
The total value of funds acquired by Auxilius Pharma Oncology sp. z o.o. is PLN 1 million.
Auxilius Pharma Oncology Sp. z o.o. operates in the complex generics market in the field of oncology. After the R&D phase, the company plans sale in the USA (under the supervision of the FDA (U.S. Food and Drug Administration), and then in Europe (under the supervision of the EMA (European Medicines Agency).
Generics, as substitutes of original medications, must meet the same standards of quality, safety and effectiveness.
related posts
Can the contribution of shares in the form of a contribution in kind be treated as a disposal of shares benefiting from the CIT exemption for income of alternative investment companies (in Poland called: “ASI”)?
Can the contribution of shares in the form of a contribution in kind be treated as a disposal of shares benefiting from the CIT exemption for income of alternative investment companies (in Poland called: “ASI”)?Income of a Polish family foundation from its participation in a Luxembourg-based Societe en commandite speciale (“SCSp”) vs. CIT exemption.
Income of a Polish family foundation from its participation in a Luxembourg-based Societe en commandite speciale (“SCSp”) vs. CIT exemption.